Fig. 4

Overexpressed AC010883.5 activates the MAPK signaling pathway and promoted C33A cell progression. A. Western blots of ERK1/2, p-ERK1/2, MEK1/2, and p-MEK 1/2 protein in SiHa cells under AC010883.5 treatment (silenced vs. control) and C-33A cells under AC010883.5 (overexpressed vs. control). B. CCK-8 analysis of viable C-33A cells in a vehicle or PD98059-treated C-33A cells under AC010883.5 treatment (overexpressed vs. control). C. BrdU incorporation analysis of proliferative C-33A cells in a vehicle or PD98059-treated C-33A cells under AC010883.5 treatment (overexpressed vs. control). D. Quantification of flow cytometry results in C33-A cells under AC010883.5 treatment (overexpressed vs. control). E. Flow cytometry analysis apoptotic C-33A cell in a vehicle or PD98059-treated C-33A cells under AC010883.5 treatment (overexpressed vs. control). F. Transwell migration analysis of migrative C-33A cell in a vehicle or PD98059-treated C-33A cells under AC010883.5 treatment (overexpressed vs. control). G. Transwell invasive analysis of invasive C-33A cell in a vehicle or PD98059-treated C-33A cells under AC010883.5 treatment (overexpressed vs. control). H. Wound healing analysis of migrative C-33A cells in vehicle or PD98059-treated C-33A cells in a vehicle or PD98059-treated C-33A cells under AC010883.5 treatment (overexpressed vs. control). I. Western blots of MAPK signal molecules in a vehicle or PD98059-treated C-33A cells under AC010883.5 treatment (overexpressed vs. control). N = 3; *P < 0.05, **P < 0.01, and ***P < 0.001. a: Vector; b: oeAC010883.5; c: PD98059 + Vector; d: PD98059 + oeAC010883.5; Abbreviations: MAPK, mitogen-activated protein kinase; ERK1/2, extracellular signal-regulated kinase 1/2; p-ERK1/2, phosphorylated ERK1/2; MEK1/2, MAPK kinase 1/2; p-MEK1/2, phosphorylated MEK1/2; CCK-8, Cell Counting Kit‐8; BrdU, 5‐Bromo-2'-deoxyuridine